In re Entresto (Sacubitril/Valsartan), Appeal Nos. 2023-2218, -2220, -2221 (Fed. Cir. Jan. 10, 2025)
In our Case of the Week, the Federal Circuit revived Novartis’s US Patent No. 8,101,659 by reversing the district...more
Mirror Worlds Technologies, LLC v. Meta Platforms, Inc., Appeal Nos. 2022-1600, -1709 (Fed. Cir. Dec. 4, 2024)
In this appeal from the United States District Court for the Southern District of New York, the Federal...more
12/10/2024
/ Appeals ,
Cross-Appeals ,
Doctrine of Equivalents ,
En Banc Review ,
Generic Drugs ,
Inter Partes Review (IPR) Proceeding ,
Noninfringement ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Industry ,
Summary Judgment ,
Technology
Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., Appeal No. 2023-1169 (Fed. Cir. June 25, 2024)
In the Court’s only precedential patent opinion last week, the Federal Circuit reversed the district court’s dismissal of...more